Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome.

ABSTRACT:

Introduction

Treatment-resistant nephrotic syndrome is a rare form of glomerular disease that occurs in children and adults. No Food and Drug Administration-approved treatments consistently achieve remission of proteinuria and preservation of kidney function. CD80 (B7-1) can be expressed on injured podocytes, and administration of abatacept (modified CTLA4-Ig based on a natural ligand to CD80) has been associated with sustained normalization of urinary protein excretion and maintenance of glomerular filtration rate in experimental and clinical settings.

Methods

In this report, we describe the rationale for and design of a randomized, placebo-controlled, clinical trial of abatacept in patients with treatment-resistant nephrotic syndrome caused by focal segmental glomeruloscle

SUBMITTER: Trachtman H 

PROVIDER: S-EPMC5762951 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature